Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trial
National Natural Science Foundation of China, Beijing Xisike Clinical Oncology Research Foundation, and Sci-Tech Project Foundation of Guangzhou.
Authors
- Mian Xi (ORCID: https://orcid.org/0000-0002-8088-0970)
- Li Zhang (ORCID: https://orcid.org/0000-0002-2836-5197)
- Mengzhong Liu (ORCID: https://orcid.org/0000-0001-7463-4514)
- Yihong Ling (ORCID: https://orcid.org/0000-0002-6433-3213)
- Yingxin Lv
- Yujia Zhu (ORCID: https://orcid.org/0000-0002-8523-0125)
- Baoqing Chen (ORCID: https://orcid.org/0000-0001-9807-7425)
- Ruixi Wang (ORCID: https://orcid.org/0009-0005-4056-9618)
- Qiaoqiao Li (ORCID: https://orcid.org/0000-0002-6299-4966)
- Shiliang Liu (ORCID: https://orcid.org/0000-0001-5830-5171)
- Yadi Yang (ORCID: https://orcid.org/0000-0001-6526-2229)
- Yonghong Hu
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- State Key Laboratory of Oncology in South China
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.eclinm.2024.102806
- Citations
- 7
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China